文献速递浆细胞疾病

来那度胺联合低剂量地塞米松持续治疗亚洲不适合移植初诊多发性骨髓瘤患者:FIRST试验亚组分析

Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
PubMed 文献 · Br J Haematol · 2017-01-20

FIRST试验亚组分析纳入来自中国大陆、韩国和台湾的114例不适合移植的初诊多发性骨髓瘤亚洲患者,评估来那度胺联合低剂量地塞米松持续治疗(Rd持续)、Rd治疗18个周期(Rd18)与美法仑+泼尼松+沙利度胺(MPT)的安全性和有效性。Rd持续组的总缓解率为77.8%,MPT组为57.5%,Rd18组为65.8%;Rd持续组较MPT组疾病进展或死亡风险降低39%,较Rd18组降低35%。Rd持续组3年生存率为70.2%,MPT组为56.4%,Rd18组为58.1%。

要点

  • 亚洲亚组中Rd持续治疗的总缓解率为77.8%,MPT组为57.5%,Rd18组为65.8%。
  • Rd持续组较MPT组疾病进展或死亡风险降低39%,较Rd18组降低35%。
  • Rd持续组3年生存率为70.2%,MPT组为56.4%,Rd18组为58.1%。

核心结论

  • Rd持续治疗在亚洲不适合移植的初诊多发性骨髓瘤患者中是安全有效的。

研究设计与样本

  • FIRST试验的亚组分析,纳入来自中国大陆、韩国和台湾的114例不适合移植的初诊多发性骨髓瘤亚洲患者,评估Rd持续、Rd18和MPT治疗。

主要发现

  • 总缓解率:Rd持续组77.8%,MPT组57.5%,Rd18组65.8%。
  • Rd持续组较MPT组疾病进展或死亡风险降低39%,较Rd18组降低35%。
  • 3年生存率:Rd持续组70.2%,MPT组56.4%,Rd18组58.1%。
  • Rd持续组与MPT组常见的3/4级不良事件分别为中性粒细胞减少(25.0% vs 43.6%)、感染(19.4% vs 28.2%)和贫血(19.4% vs 15.4%)。
  • 血栓栓塞事件发生率低,未观察到第二原发恶性肿瘤。

关键数值与推荐

  • 总缓解率:Rd持续组77.8%,MPT组57.5%,Rd18组65.8%。
  • 疾病进展或死亡风险:Rd持续组较MPT组降低39%,较Rd18组降低35%。
  • 3年生存率:Rd持续组70.2%,MPT组56.4%,Rd18组58.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Given genetic differences between Asian and Western populations, this subanalysis of the FIRST trial examined the safety and efficacy of Rd (given continuously or for 18 cycles [Rd18]) and MPT (melphalan, prednisone, thalidomide) in 114 Asian patients from Mainland China, South Korea and Taiwan. Efficacy and safety with Rd continuous in Asian patients were consistent with those in the overall study population. The overall response rates were 77·8% for Rd continuous, 57·5% for MPT and 65·8% for Rd18. The risk of progression or death was reduced by 39% with Rd continuous versus MPT and by 35% with Rd continuous versus Rd18. Rd continuous improved the 3-year survival rate compared with MPT (70·2% vs. 56·4%) and Rd18 (58·1%). Common grade 3/4 adverse events in the Rd continuous and MPT arms were neutropenia (25·0% vs. 43·6%), infection (19·4% vs. 28·2%) and anaemia (19·4% vs. 15·4%), respectively. Thromboembolic event rates were low, and no second primary malignancies were observed. Rd continuous is safe and effective in transplant-ineligible Asian patients with NDMM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017. PMID: 28106903. doi:10.1111/bjh.14465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。